List of adverse effects of pazopanib
This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence.[1][2][3][4][5]
Very common
Very common (>10% incidence) adverse effects include:
- Reduced appetite
- Headache
- Taste changes
- High blood pressure[Note 1]
- Diarrhoea
- Abdominal pain
- Nausea
- Vomiting
- Hair colour change
- Hand-foot syndrome
- Hair loss
- Rash
- Fatigue
- Increased alanine aminotransferase
- Increased aspartate aminotransferase
- Tumour pain‡
- Myelosuppression‡[Note 2]
- Stomatitis‡
- Exfoliative rash‡
- Skin hyperpigmentation‡
- Weight loss‡
Common
Common (1–10% incidence) adverse effects include:
- Tumour pain†
- Myelosuppression†[Note 3]
- Underactive thyroid
- Dehydration
- Low level of phosphate in the blood
- Dizziness
- Lethargy
- Paraesthesia
- Peripheral sensory neuropathy
- Blurred vision
- Hot flush
- Venous thromboembolic event
- Flushing
- Nose bleed
- Voice anomalies
- Shortness of breath
- Coughing up blood
- Stomatitis
- Indigestion
- Flatulence
- Abdominal distension
- Dry mouth
- Mouth ulceration
- Hyperbilirubinaemia
- Abnormal liver function
- Hepatotoxicity
- Skin hypopigmentation
- Dry skin
- Itchiness
- Erythema
- Skin depigmentation
- Hyperhidrosis
- Joint pain
- Muscle aches
- Muscle spasms
- Protein in the urine
- Mucosal inflammation
- Weakness
- Oedema
- Chest pain
- Weight loss†
- Increased blood creatinine
- Lipase increased
- Decreased white blood cell count
- Blood TSH decreased
- Amylase increased
- Gamma-glutamyltransferase increased
- Increased blood pressure
- Increased blood urea
- Abnormal liver function test
- Gingival infection‡
- Dizziness
- Insomnia
- Peripheral sensory neuropathy
- Heart dysfunction
- Blurred vision
- Low heart rate
- Left ventricular dysfunction
- Bleeding (including haemorrhage)
- High blood sugar
- Low blood sugar
Uncommon
Uncommon (0.1–1% incidence) adverse effects include:
- Torsades de pointes
- Heart failure
- Liver failure
- GI perforation (may be fatal)
- Fistula formation
Rare
Rare (<0.1% incidence) adverse effects include:
- Reversible posterior leucoencephalopathy syndrome
Notes
† Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma.
‡ Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.
References
- ↑ "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 2 February 2014. Retrieved 27 January 2014.
- ↑ "VOTRIENT (pazopanib hydrochloride) tablet, film coated" (PDF). DailyMed. GlaxoSmithKline LLC. November 2013. Archived from the original on 2 February 2014. Retrieved 27 January 2014.
- ↑ "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Archived (PDF) from the original on 4 February 2014. Retrieved 27 January 2014.
- ↑ "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Archived from the original on 1 February 2014. Retrieved 27 January 2014.
- ↑ "PRODUCT INFORMATION VOTRIENT® TABLETS" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Archived from the original on 25 June 2016. Retrieved 27 January 2014.
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.